Analysis of local control in patients with non-Hodgkin's lymphoma according to the WHO classification.

Abstract

PURPOSE:

To analyze the influence of radiotherapy doses, chemotherapy doses, and clinical parameters on in-field disease control to assess the optimal radiation doses for treatment of non-Hodgkin's lymphoma according to the newly proposed WHO classification.

PATIENTS AND METHODS:

Subjects consisted of 35 extranodal marginal-zone B-cell lymphomas of mucosa-associated lymphoid tissue (MALT) type, 75 diffuse large B-cell lymphomas (DLBCL), 14 follicular lymphomas, 17 extranodal natural killer (NK)/T-cell lymphomas, nasal type, eight unclassified peripheral T-cell lymphomas, four anaplastic large-cell lymphomas, T/null cell type, and five others. 59 patients received radiotherapy alone. 98 patients received CHOP, modified CHOP, or more intensive chemotherapy, and six patients were treated with other combination.

RESULTS:

No patients with MALT lymphoma had in-field local recurrence. There were no recurrences in DLBCL patients who received chemotherapy in which the doses of adriamycin were > 200 mg/m(2), nor in DLBCL patients who were treated with > 45 Gy. Only nine of 15 patients with T-cell lymphoma treated with < or = 50 Gy and three of five patients treated with > 50 Gy had local control. The dose of adriamycin had no influence on local control of T-cell lymphoma.

CONCLUSION:

T/NK-cell lymphomas were more radioresistant than B-cell lymphomas. The prognosis for peripheral T/NK-cell lymphomas is poor even when treated by irradiation combined with chemotherapy.

• Authors: Koh-Ichi Sakata, Masaaki Satoh, Masanori Someya, Hisayasu Nagakura, Atushi Oouchi, Kensei Nakata, Katsuhisa Kogawa, Kazumitsu Koito, Masato Hareyama, Tetsuo Himi
• Journal: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] (Strahlenther Onkol) Vol. 181 Issue 6 Pg. 385-91 (Jun 2005) ISSN: 0179-7158 [Print] Germany
• PMID: 15925981 (Publication Type: Journal Article)

Chemical References

• Antibiotics, Antineoplastic
• Doxorubicin

Topics

• Adult
• Aged
• Antibiotics, Antineoplastic (therapeutic use)
• Combined Modality Therapy
• Doxorubicin (therapeutic use)
• Female
• Follow-Up Studies
• Humans
• Lymphoma, B-Cell (classification, drug therapy, mortality, radiotherapy)
• Lymphoma, B-Cell, Marginal Zone (drug therapy, mortality, radiotherapy)
• Lymphoma, Non-Hodgkin (classification, drug therapy, mortality, radiotherapy)
• Male
• Middle Aged
• Retrospective Studies
• Survival Analysis
• Time Factors